Skip to content
PreclinicalResearch compound

BAM15

Experimental fat-burning compound: caused weight loss and better insulin sensitivity in obese mice, not studied in humans.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

BAM15 vial

DETAILED OVERVIEW

What is BAM15?

BAM15 is an experimental compound, a mitochondrial uncoupler: in the mitochondria (the part of the cell that produces energy) it releases the energy of burned fuel as heat instead of letting the cell use it. The old weight-loss agent DNP worked on the same principle and led to deaths; in experiments BAM15 acts more selectively. It has not been approved as a medicine anywhere and is sold as a research chemical.

In obese mice it switched on heat production in brown fat, improved insulin sensitivity and caused weight loss without damaging the heart. There is no active human study, so its effects and safety in people are unknown. It can cause overheating and a dangerous rise in blood lactic acid. Black-market products may be counterfeit or contaminated with DNP, which is life-threatening. It must not be used in pregnancy or breastfeeding, because it may endanger the baby's development. It is not listed separately on the anti-doping list, but the general ban on unapproved substances can lead to a sanction in competitive sport.

Mechanism

Mitochondrial protonophore uncoupler, DNP-adjacent mechanism + selective for the inner mitochondrial membrane (safer therapeutic window)

Half-life

~3-5 hours (mouse extrapolation)

Onset time

BAT-activation marker acute 1-2 h; metabolic-rate elevation 1-2 weeks

Legal status

Research-only – NOT an FDA / EMA Rx in any jurisdiction. WADA NOT explicitly listed; S0 catch-all + monitoring concern applies.

Data console

Lab data

Androgenic:AnabolicN/A (not an AAS, mitochondrial uncoupler)
AR bindingNOT a classical receptor-binding compound…
Active half-life~3-5 hours (mouse extrapolation)
Detection windowNO human-detection-validated assay exists as of January 2026. WADA-accredited LC-MS/MS detection method developed only on preclinical mouse-plasma baseline.
AromatizationDoes not aromatize (not a steroid – mitochondrial uncoupler protonophore). No CYP19 interaction; the estrogen axis is directly unaffected.
HepatotoxicityUnknown – preclinical-only; long-term human data is missing. DNP-adjacent mechanism mortality-risk concern (DNP fatalities span 60+ years of history) BUT BAM15 preclinical evidence shows a safer therapeutic window (Alexopoulos 2020 PMID 32848134). Mouse chronic 8-week 0.5 mg/kg/day dosing shows ALT/AST elevation <2x baseline (preliminary); human-trial data is ZERO.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Hyperthermia (elevated body temperature): the uncoupling mechanism produces heat and can cause overheating, the principal danger of DNP-class compounds. No human data; preclinical mouse models show mild rise (+0.3–0.5°C).
  • Increased metabolic rate and resting heart rate: elevated heat production and energy expenditure raise heart rate and cardiovascular load.
  • Elevated lactate / risk of lactic acidosis: disrupting mitochondrial ATP synthesis can shift metabolism toward anaerobic pathways and lactate accumulation.
  • Excessive sweating and fluid loss: heat production triggers compensatory sweating, which can cause dehydration and electrolyte imbalance.
  • Possible liver enzyme elevation (ALT/AST): due to hepatic uncoupling stress; mouse models show <2x baseline rise after 8 weeks, no human data.
  • Fatigue, weakness and reduced exercise capacity: lower cellular ATP production can cause an energy-deficit state.
  • Unknown human toxicity profile: no active human clinical trial as of 2026, so long-term and rare adverse effects are entirely uncharacterized.

Contraindications · 7

  • Concurrent use of DNP or other mitochondrial uncouplers: identical protonophore mechanism, additive hyperthermia and potentially fatal toxicity.
  • Hyperthyroidism or other conditions causing hyperthermia: additive heat production and metabolic acceleration.
  • Serious cardiovascular disease (coronary artery disease, severe angina, arrhythmia): the raised metabolic rate and heart rate impose dangerous cardiac strain.
  • Pregnancy and breastfeeding: no teratogenicity data, and mitochondrial uncoupling may pose fetal developmental risk.
  • Pre-existing liver or kidney disease: hepatic uncoupling stress and lactic acidosis risk impose increased organ burden.
  • Any human use outside a clinical trial: a preclinical (animal-only) research compound with no approved human dosing or safety profile as of 2026.
  • Black-market (UGL) sourced product: counterfeiting and DNP contamination documented in 2023–2024, making it unpredictable and potentially life-threatening.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about BAM15?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.